U.S. markets close in 2 hours 2 minutes

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.31+0.22 (+1.60%)
As of 01:58PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close14.09
Bid14.25 x 800
Ask14.27 x 1000
Day's Range13.98 - 14.33
52 Week Range12.24 - 28.06
Avg. Volume2,644,857
Market Cap2.311B
Beta (5Y Monthly)0.67
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ACAD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ACADIA Pharmaceuticals Inc.
    Daily – Vickers Top Buyers & Sellers for 06/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Motley Fool

    Why Acadia Pharmaceuticals Stock Is Crashing Today

    An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.

  • Benzinga

    Why Acadia Pharma Shares Are Plunging Today

    A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-related psychosis. Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. Related: Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis. "We are disappoin

  • MarketWatch

    Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote

    Shares of Acadia Pharmaceuticals Inc. were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company's treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks. The FDA, which is not required to follow the advice of the committee but often does, is expected to decide whether to app